ARQT - NASDAQ

Arcutis Biotherapeutics, Inc.

ARQT·NASDAQ

$21.35

-0.56%

HealthcareBiotechnology

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.67B

EPS-0.1300

P/E Ratio-164.23

Earnings Date08/05/2026

432.97M

Assets

24%

3Y-4.0%

5Y+45.0%

10Y+11237.0%

243.49M

Total Liabilities

27%

3Y+2.0%

5Y+781.0%

10Y+2663.0%

189.48M

Total Equity

20%

3Y-10.0%

5Y-30.0%

10Y-3895.0%

Arcutis Biotherapeutics, Inc. Funding & Solvency Profile

ARQT · NASDAQ

Current Assets

Cash & Cash Equivalents42.91M

Net Receivables146.23M

Inventory22.63M

Other Current Assets21.39M

Total Current Assets411 M

Non-Current Assets

Property, Plant & Equipment5.51M

Goodwill & Intangible Assets14.81M

Long-Term Investments0.00

Other Non-Current Assets1.42M

Total Non-Current Assets7 M

Total Assets

432.97M

Financial Health Analysis

Current Ratio

3.17x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.29x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

281 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Arcutis Biotherapeutics, Inc. Balance Sheet

ARQT • NASDAQ

Arcutis Biotherapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	42.9M	71.3M	88.4M	53.6M	98M	65.1M	63.3M	39.4M	3.4M
Short-Term Investments	178.1M	156.6M	183.5M	355.9M	290.6M	219.4M	37.9M	11.5M	0.0
Cash & Short-Term Investments	221M	228M	271.9M	409.6M	388.6M	284.4M	101.3M	50.9M	3.4M
Net Receivables	146.2M	73.1M	25.8M	8.5M	362K	510K	0.0	0.0	0.0
Accounts Receivables	146.2M	73.1M	25.8M	8.5M	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	362K	510K	0.0	0.0	0.0
Inventory	22.6M	14.5M	13.1M	7.5M	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	11.5M	10.1M	7.4M	6.1M	6.3M	3.3M	40K	221K
Other Current Assets	21.4M	8.8M	9.5M	4.5M	7.7M	1.5M	1.9M	0.0	0.0
Total Current Assets	411.2M	335.8M	330.4M	437.4M	402.8M	292.8M	106.5M	51.1M	3.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.5M	3M	3.9M	4.6M	5.3M	5.4M	491K	0.0	0.0
Intangible Assets	14.8M	9.5M	6.4M	7.2M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	14.8M	9.5M	6.4M	7.2M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.4M	596K	596K	78K	78K	78K	47K	0.0	0.0
Total Non-Current Assets	21.7M	13.1M	10.9M	11.9M	5.4M	5.4M	538K	0.0	0.0
Total Assets	433M	348.9M	341.4M	449.3M	408.2M	298.3M	107M	51.1M	3.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	12.5M	14.2M	12M	8.8M	7.4M	7.1M	1.4M	1.8M	537K
Accounts Payable	12.5M	14.2M	12M	8.8M	7.4M	7.1M	1.4M	1.8M	537K
Accrued Expenses	0.0	45.2M	14.9M	14M	9.1M	15.3M	3.4M	756K	155K
Short Term Debt	1M	0.0	0.0	657K	433K	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	820K	735K	657K	0.0	0.0	178K	0.0	0.0
Other Current Liabilities	116.3M	20.7M	19.1M	13.7M	16.4M	176K	225K	116K	0.0
Total Current Liabilities	129.8M	81M	46.7M	37.8M	33.3M	22.6M	5.2M	2.7M	692K
NON-CURRENT LIABILITIES
Long Term Debt	5.3M	107.2M	201.8M	197.8M	72.4M	0.0	0.0	0.0	966K
Other Non-Current Liabilities	108.4M	570K	849K	0.0	25K	82K	184K	72.4M	7.2M
Total Non-Current Liabilities	113.7M	110.3M	206M	201.9M	77.1M	5M	313K	72.4M	8.1M
Capital Lease Obligations	0.0	3.4M	4.1M	4.8M	4.8M	5M	307K	0.0	0.0
Total Liabilities	243.5M	191.3M	252.7M	239.7M	110.5M	27.6M	5.6M	75.1M	8.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	166.5M	72.3M	7.2M
Common Stock	12K	12K	9K	6K	5K	4K	0.0	0.0	0.0
Additional Paid-In Capital	0.0	1.3B	1.1B	930.4M	706.2M	472.6M	1.2M	289K	28K
Retained Earnings	-1.1B	-1.1B	-981.9M	-719.8M	-408.3M	-202M	-66.3M	-24.3M	-5M
Accumulated Other Comprehensive Income/Loss	-44K	-7K	4K	-1.1M	-255K	-2K	-999.0	0.0	0.0
Other Total Stockholders' Equity	1.3B	0.0	0.0	0.0	0.0	0.0	0.0	-72.3M	-7.2M
Total Stockholders' Equity	189.5M	157.5M	88.7M	209.6M	297.7M	270.6M	101.5M	-24M	-5M
Total Equity	189.5M	157.5M	88.7M	209.6M	297.7M	270.6M	101.5M	-24M	-5M
SUMMARY
Total Liabilities & Equity	433M	348.9M	341.4M	449.3M	408.2M	298.3M	107M	51.1M	3.8M
Total Investments	178.1M	156.6M	183.5M	355.9M	290.6M	219.4M	37.9M	11.5M	0.0
Total Debt	6.3M	110.6M	205.9M	202.5M	77.6M	5M	307K	0.0	966K
Net Debt	-36.6M	39.3M	117.5M	148.9M	-20.4M	-60.1M	-63M	-39.4M	-2.5M
Shares Outstanding	122,479,487	122,479,487	122,479,487	122,479,487	122,479,487	122,479,487	122,479,487	122,479,487	122,479,487

SEC Filings

ARQT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 21, 2026	April 21, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 03, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 28, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 28, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 06, 2025	August 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 06, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 111 filings

Related Guides

Blog Categories

Continue your ARQT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.